Waldenström's Macroglobulinemia
Information
- Disease name
- Waldenström's Macroglobulinemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00398710 | Completed | Phase 2 | A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia | October 2006 | October 2011 |
| NCT01788020 | Completed | Phase 3 | Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | November 2013 | April 2024 |
| NCT02165397 | Completed | Phase 3 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | July 7, 2014 | November 7, 2019 |
| NCT03053440 | Completed | Phase 3 | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) | January 25, 2017 | June 21, 2022 |
| NCT03697356 | Recruiting | Phase 2 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia | March 6, 2019 | June 30, 2026 |
| NCT05326308 | Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | April 26, 2022 | April 2027 | |
| NCT05979948 | Recruiting | Phase 2 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia | August 1, 2023 | December 1, 2025 |